Cefpodoxime proxetil
Edina Avdic, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Cefpodoxime proxetil is a topic covered in the
Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --
INDICATIONS
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved